NCT05080010View on ClinicalTrials.gov

Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Retinoblastoma
Interventions
DRUG

3 cycles chemotherapy

Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.

Trial Locations (1)

510000

RECRUITING

Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER